Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trials in Tucson, Arizona
4 recruitingTucson, Arizona
Showing 1–4 of 4 trials
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1Phase 2
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled21 locationsNCT03972657